ANDA Review Consistency Could Emerge As A GDUFA Problem

Industry officials are concerned all the new FDA hires to handle generic drug user fee program issues will lead to varied interpretations of agency policy and potentially create first-to-file or other problems.

As FDA remakes the ANDA review system into one that is more speedy and formal, it likely will have to battle consistency problems, particularly as new employees adapt to the soon-to-be-ticking review clock.

The agency plans to train new hires on the new policies, but industry is concerned the inexperienced staff may clash with veterans over interpretations of the new GDUFA-inspired review criteria.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By 

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.

Prasad Says Involvement In US FDA Product Approvals Will Mirror Prior CBER Directors

 

The remarks from the new CBER director suggest Prasad will not be involved in most product-specific decisions.

Scientists Work With AI To Uncover ‘Unexpected’ Drug Combos For Breast Cancer

 

A UK research team has used artificial intelligence to find new treatments for cancer using existing US Food and Drug Administration-approved medicines that are not normally not used for the disease.

Saving Part D: US Medicare Advisors Sound The Alarm

 

The US Medicare Payment Advisory Commission worries that Medicare prescription drug market trends may cause the stand-alone plan portion of the program to “wither away,” which could take the traditional fee-for-service side of Medicare with it.

More from North America

Clinical Trials Nonprofit Fights for Access Despite DEI Crack-Down

 
• By 

The Clinical Trials Access Collaborative (CTAC) will build on a pilot program's work to bolster community-based clinical research infrastructure so "anyone who wants to participate in clinical trials can and do it closer to home,” CEO Tesheia Harris said in an interview.

US FDA Cell-Gene Therapy Head Says Agency Has Revived Stalled Programs

 

CBER's Nicole Verdun wants rare disease sponsors with stalled treatments to circle back because the FDA's evolved thinking on clinical trial designs may offer another opportunity for cast away products.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By 

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.